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Introduction: From 1998 to 2002, we performed a trial of prospec-
tive limited resection for pulmonary ground-glass opacity lesions 
2 cm or smaller. This is the second report on the long-term outcome.
Methods: The enrollment criteria of the trial were as follows: pulmo-
nary peripheral nodule less than 2 cm, diagnosis or suspected diag-
nosis of clinical T1N0M0 carcinoma with ground-glass opacity and 
lack of evident pleural indentations or vascular convergence on high-
resolution computed tomography. Limited-resection (wedge or seg-
ment) specimens were intraoperatively examined by frozen section. 
If the nodule was confirmed as Noguchi type A or B with a resection 
margin of greater than 1 cm, the incision was sutured and the patient 
followed up. The median surveillance period was 10 years.
Results: In a total of 50 enrolled participants, there were two Noguchi 
type A, 23 type B and 15 type C adenocarcinomas; five atypical ade-
nomatous hyperplasias, four fibroses, and one granuloma. Although 
there were no patients with recurrence within the first 5 years, in 
four patients who underwent limited-resection pulmonary adenocar-
cinoma developed more than 5 years after the initial resection, of 
either cut-end recurrence or metachronous primary disease.
Conclusions: Of 26 patients who underwent limited resection, adeno-
carcinoma developed in four after more than 5 years. These were pos-
sibly cut-end recurrences. We concluded that 5 years is not a sufficient 
period for follow-up, and that limited resection should still be done 
only in a trial setting, even for small ground-glass opacity lesions.
Key Words: Lung cancer, Adenocarcinoma, Limited resection, 
Ground-glass opacity, Noguchi classification.
(J Thorac Oncol. 2012;7: 1563–1566)
In 2005, we reported the study design, methods, and pre-liminary results of our previous prospective trial on limited 
resection for pulmonary ground-glass opacity (GGO) nodules 
at the median follow-up point of 50 months.1 At that time, 26 
patients who had undergone limited resection (two for Noguchi 
type A, 23 for type B, and one for type C adenocarcinomas)2 
were free from recurrence. In those 26 patients, Noguchi type 
A and B lesions seemed to be in situ, noninvasive carcinomas, 
and we speculated that limited resection could be curative sur-
gery for these diseases. In the trial, 14 patients with Noguchi 
type C lesions underwent lobectomy and lymph node dissec-
tion, and no nodal involvement, lymphatic permeation, or 
vascular invasion was observed. Therefore, we speculated that 
even patients with Noguchi type C lesions in our trial could 
also have been curatively treated by limited resection.
However, during continued long-term follow-up, in 
four of the 26 patients who underwent limited resection, pul-
monary adenocarcinoma developed in areas surrounding the 
 initial limited-resection cut-end staples more than 5 years 
after the initial surgery. We speculated that these might have 
been cut-end recurrences. We previously reported the details 
of three of these four patients in 2010 and warned of the pos-
sibility of late recurrence after limited resection, even for 
small GGO lesions.3 With the median follow-up period of the 
patients enrolled in this trial having reached 10 years, we set 
out to determine the long-term recurrence rate of small GGO 
lung adenocarcinomas after limited resection.
PATIENTS AND METHODS
Patients
From 1998 to 2002, we enrolled 50 patients in this study.1 
Enrollment criteria were: tumor less than 2 cm in diameter, 
diagnosed as or suspected to be a clinical T1N0M0  carcinoma4 
in the lung periphery on computed tomography (CT); high-
resolution CT findings suggestive of a Noguchi type A or B 
adenocarcinoma (i.e., GGO and lack of evident pleural inden-
tation or vascular convergence). Patients with a history of 
malignancy within the previous 5 years and those who were 
not indicated for lobectomy and systematic lymph node dis-
section were excluded. Written informed consent was obtained 
from each participant. The study protocol was reviewed by 
the Institutional Review Board of the National Cancer Center 
Hospital East (Chiba, Japan) and was approved in July 1998.
We performed limited resection, wedge resection, or 
segmentectomy as appropriate. We performed segmentectomy 
when the nodule was located deep in the middle of a segment 
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or could not be located intraoperatively. A frozen-section spec-
imen was examined intraoperatively to identify Noguchi type 
A or B lesions, as described in detail in our previous report.1 
If the tumor was confirmed as Noguchi type A or B with a 
resection margin greater than 1 cm, the wound was closed and 
the patient followed up on an outpatient basis. If the resected 
margin was insufficient, an additional margin was resected. 
If the tumor was a primary malignancy, but not Noguchi type 
A or B lesions, lobectomy and systematic lymph node dis-
section were additionally performed. Patients were followed 
up on an outpatient basis at a minimum of every 6 months 
by physical check-up, plain chest radiography, and laboratory 
testing. Patients who underwent limited resection for Noguchi 
type A or B lesions had chest CT scans taken every year.
Of the 36 patients who were given intraoperative diag-
noses of Noguchi type A or B tumors or nonmalignancy, 30 
underwent wedge resection and six underwent segmentec-
tomy. We performed lobectomy and lymph node dissection in 
14 patients with intraoperative diagnoses of type C tumors. 
The final pathologic diagnosis of 50 cases was 40 adenocar-
cinomas, including two Noguchi type A, 23 type B, and 15 
type C tumors, five atypical adenomatous hyperplasias, four 
fibroses, and one granuloma.1
Statistical Analysis
The primary endpoint for analyses was the recurrence-
free proportion of patients, measured from the date of surgery 
to the date when possible recurrence was suspected for the 
first time. The last follow-up observation was censored when 
the patient was alive without any signs of recurrence, was lost 
to follow-up, or died from any cause other than lung cancer. 
We also measured overall survival from the date of surgery 
to the date of death from any cause. The recurrence-free pro-
portion curve was plotted using the Kaplan–Meier method 
and the statistical significances of difference between the 
subgroups were determined by the two-sided log-rank test. 
A p value of less than 0.05 was considered to represent a 
statistically significant difference. We used statistical analysis 
software, Dr. SPSS II for Windows, Standard Version 11.0 
(SPSS Inc., Chicago, IL) for all analyses.
RESULTS
Long-Term Outcome Among  
40 Adenocarcinoma Patients
After the preliminary results were published, we continued 
to observe the 40 adenocarcinoma patients with a median 
 follow-up period of 10 years. There were no patients with 
recurrence within the first 5 years. However, in four patients 
who had undergone limited resection, pulmonary adenocarci-
noma developed in the area surrounding the cut-end staples 
of the initial limited resection 5 years or later after the initial 
surgery. Of these, three had Noguchi type B tumors, and one 
had a type C tumor, which was initially diagnosed as type B 
by frozen-section examination. Therefore, this patient only 
underwent wedge resection. After detailed discussion, he 
decided not to have any further treatment on his own will. All 
the other 14 type C patients who underwent lobectomy and 
lymph node dissection are free from recurrence or metachro-
nous primary disease at the time of writing (Fig. 1).
The characteristics of the four patients in whom pul-
monary adenocarcinoma developed around the area of the 
cut-end scar are shown in the Table 1. All of them initially 
underwent wedge resection, and had intraoperative frozen-
section diagnoses of Noguchi type B. We reported the findings 
in patients No. 1 to 3 in detail previously.3 Solid nodular shad-
ows appeared at the cut-ends of initial limited-resection sites, 
more than 5 years after the initial surgery in all four patients. 
These secondary lesions were cytohistologically diagnosed 
as adenocarcinomas, and they showed the same epidermal 
growth factor receptor mutation status as the primary lesions 
in three of the four patients. Therefore, we diagnosed them 
to be possible cut-end recurrences rather than metachronous 
primary diseases.
Figure 2A shows the recurrence-free proportion curve 
of the 40 adenocarcinoma patients. The 5- and 10-year recur-
rence-free proportions were 100% and 92%, respectively. 
There was one patient who died from lung cancer and one who 
died from other malignant disease. The overall 5- and 10-year 
survival rates were 100% and 95%, respectively. Figure 2B 
shows the recurrence-free proportion curve of the 26 patients 
who underwent limited resection, in comparison with that of 
the 14 patients who underwent lobectomy. The 5- and 10-year 
recurrence-free proportions of the limited-resection patients 
were 100% and 87%, respectively. There were no statistically 
FIGURE 1. The intraoperative and final pathologic diagno-
sis, operative procedure, and long-term outcome of 40 ade-
nocarcinoma patients; 1 patient had a type C tumor which 
was intraoperatively diagnosed as type B by frozen-section 
examination, and this patient underwent wedge resection 
only (asterisk). LND, lymph node dissection.
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significant differences in recurrence-free proportion between 
the limited resection and lobectomy groups (p = 0.136).
DISCUSSION
During the monitoring of the patients who had undergone 
limited resection (median follow-up period, 10 years), three 
patients with Noguchi type B and one with Noguchi type C 
tumors at the final pathologic diagnosis developed pulmonary 
adenocarcinoma 5 years or more after limited resection. In all 
cases, the second cancers developed in the areas surrounding 
the initial limited-resection cut-end staples, which strongly 
suggests they were cut-end recurrences rather than metachro-
nous primary cancer. However, in one of the four patients, the 
second cancer harbored only one of the two point mutations 
observed in the EGFR gene of the first cancer, and therefore we 
strongly speculate that this second cancer was a metachronous 
primary lesion.3 Regardless of the etiology, the disease-control 
rate of the limited resection in our trial was unacceptably low, 
at 85% (22 of 26). The minimum resection margin of greater 
than 1 cm in our trial setting may have been insufficient to 
completely remove cancer cells by limited resection.
Surgical resection was not indicated in two of the four 
patients because their second cancer in these areas had already 
disseminated into the thoracic cavity upon detection. Although 
there were no statistically significant differences in recurrence-
free proportion between the limited resection and lobectomy 
groups in the current series, this lack of significance have been 
caused by a beta error. All 14 patients with invasive type C ade-
nocarcinoma who underwent standard lobectomy and lymph 
node dissection remain free from recurrence or metachronous 
cancer at the time of writing this article. Lobectomy might be the 
curative treatment of choice even for small GGO adenocarcino-
mas. Care must be taken in determining the indication for lim-
ited resection, which should be assessed further in a trial setting.
The most notable result in the present study is the length 
of time to recurrence. In our first report, we suggested that a 
5-year follow-up period is insufficient to conclude that the 
disease is cured, considering the probable slow-growing nature 
of GGO lesions, and that an additional 5 years of monitoring 
is necessary to yield definitive conclusions.1 We previously 
described the considerable risk of the late recurrence of 
non–small-cell lung cancer more than 5 years after curative 
surgery.5,6 These findings prompted us to continue to follow-up 
of limited-resection patients in whom we observed possible cut-
end recurrence 5 years or more after limited resection. There are 
several prospective studies of limited resection for pulmonary 
adenocarcinoma reported from Japan.7–10 In these studies, 
wedge resection was performed mostly for intraoperatively 
diagnosed noninvasive adenocarcinomas, and no recurrences 
or cancer-related deaths were observed. However, these results 
were obtained after a relatively short median follow-up period of 
29 to 51 months, which may have been insufficient to determine 
these slow-growing cancers as cured.
In Japan, a single-arm, limited-resection trial, Japanese 
Clinical Oncology Group (JCOG) 0804/West Japan Oncology 
Group (WJOG) 4507L is ongoing for subsolid T1aN0M011 
peripheral tumors with a consolidation–tumor size ratio of 
0.25 or less. A total of 330 patients had been enrolled as of 
April 2011, and therefore the 10-year follow-up results will 
not be available until 2020. Another two major randomized, 
limited-resection trials, JCOG0802 / WJOG4607L and Cancer 
TABLE 1. Characteristics of Four Patients with Possible Recurrence
No.
Size 
(mm)
Final 
Diagnosis
Site of 
Initial Recurrence
Time to 
Recurrence 
(Yrs)
Status of EGFR Mutation 
Primary / Recurrence
Treatment for 
Recurrence
Outcome 
(Yrs)
1. 20 Type B Cut-end scar 7.9 L858R and S768I/L858R Reoperation Alive (11.6)
2. 11 Type B Cut-end scar 5.5 E746-A750 del type 2/E746-A750 del type 2 Reoperation Alive (9.8)
3. 20 Type C Cut-end scar and pleural effusion 8.0 None/none EGFR-TKI Dead (9.0)
4. 15 Type B Cut-end scar and contralateral lung 10.5 L858R/L858R EGFR-TKI Alive (12.1)
EFGR, epidermal growth factor receptor. TKI, tyrosine-kinase inhibitor.
FIGURE 2. A, The recurrence-free proportion curves of 40 
adenocarcinoma patients, and (B) 26 patients who under-
went limited resection, in comparison with 14 patients who 
underwent lobectomy. LND, lymph node dissection.
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and Leukemia Group B-140503, are still in the accumulation 
phase in Japan and in the United States and Canada, respec-
tively. Their aims are to compare limited resection with stan-
dard lobectomy for T1aN0M0 peripheral non–small-cell lung 
cancer. These are ambitious projects that could raise the stan-
dard of lung cancer surgery. However, considering the possi-
bility of delayed cut-end recurrence, clinicians should refrain 
from indicating limited resection in clinical practice until the 
abovementioned trials clearly show that limited resection is 
the treatment of choice for these types of small lung cancer. 
Currently at our department, for a subsolid T1aN0M0 periph-
eral tumor with a consolidation–tumor size ratio of 0.25 or 
less, we indicate limited resection only when the patient’s 
consent is obtained after discussion based on our in-house 
and JCOG0804/ WJOG4507L limited-resection experiences. 
For a tumor with a consolidation–tumor size ratio of greater 
than 0.25, we ask the patient to participate in JCOG0802 / 
WJOG4607L trial. If the patient agrees to participate, he or 
she is randomly allocated to segmentectomy or lobectomy. If 
not, we indicate standard lobectomy and node dissection.
CONCLUSIONS
To the best of our knowledge, this is the first report 
in the literature on the long-term outcome of a prospective 
limited-resection trial of pulmonary small GGO lesions after 
a median follow-up period of 10 years. The findings of four 
possible cases of delayed cut-end recurrence clearly demon-
strate the need for long-term follow-up of more than 5 years, 
and that limited resection should still be done only in a trial 
setting, even for small GGO cancer.
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